Needham Initiates Coverage On Camp4 Therapeutics with Buy Rating, Announces Price Target of $8

Needham analyst Joseph Stringer has initiated coverage on Camp4 Therapeutics (NASDAQ: CAMP) with a Buy rating. The analyst has set a price target of $8 for the company's stock.